MedPath

Alvotech Swiss AG

🇨🇭Switzerland
Ownership
Subsidiary, Private
Employees
-
Market Cap
-
Website

Clinical Trials

34

Active:15
Completed:16

Trial Phases

2 Phases

Phase 1:21
Phase 3:12

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials

Phase 1
21 (63.6%)
Phase 3
12 (36.4%)

Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio

Phase 1
Recruiting
Conditions
Healthy Male and Female Subjects
Interventions
Biological: Geographical region 2 Entyvio
Biological: Geographical region 1 Entyvio
First Posted Date
2024-12-13
Last Posted Date
2025-05-25
Lead Sponsor
Alvotech Swiss AG
Target Recruit Count
351
Registration Number
NCT06732804
Locations
🇦🇺

Veritus Research Pty Ltd, Bayswater, Australia

🇳🇿

Investigational Site 0002, Auckland, New Zealand

🇳🇿

NZCR, Christchurch, New Zealand

Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

Phase 3
Recruiting
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2024-08-26
Last Posted Date
2025-01-10
Lead Sponsor
Alvotech Swiss AG
Target Recruit Count
748
Registration Number
NCT06570772
Locations
🇦🇷

Investigational Site 161704, Ciudad Autónoma de BuenosAires, Argentina

🇦🇷

Investigational Site 161702, Cordoba, Argentina

🇦🇷

Investigational Site 161701, Quilmes, Argentina

and more 96 locations

Pilot Study of AVT16 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-05-06
Last Posted Date
2025-03-11
Lead Sponsor
Alvotech Swiss AG
Target Recruit Count
18
Registration Number
NCT06400719
Locations
🇳🇿

CCST, Christchurch, New Zealand

Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease

Phase 3
Completed
Conditions
Chorioretinal Vascular Disease
First Posted Date
2023-08-14
Last Posted Date
2025-04-22
Lead Sponsor
Alvotech Swiss AG
Target Recruit Count
35
Registration Number
NCT05986786
Locations
🇬🇪

4001, Tbilisi, Georgia

AVT03 With Xgeva in Healthy Male Subjects

Phase 1
Completed
Conditions
This is a Phase I Study Conducted in Healthy Volunteers
Interventions
First Posted Date
2023-05-26
Last Posted Date
2025-05-15
Lead Sponsor
Alvotech Swiss AG
Target Recruit Count
208
Registration Number
NCT05876949
Locations
🇵🇱

Biokinetica, Józefów, Poland

🇿🇦

Farmovs, Bloemfontein, South Africa

🇬🇧

Richmond Pharmacology, London, United Kingdom

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.